Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Stem Cells. 2015 Apr;33(4):1200–1212. doi: 10.1002/stem.1934

Figure 6. Inhibiting A2aR In Human Th1 Cells Abrogates The Effect Of BMSC In Vivo.

Figure 6

Female NSG mice were reconstituted with human Th1 cells (5 million) and Monocytes (3 million). Within 24hrs of GVHD onset (between day 20 to day 35), the BMSC cohort was treated 3 times with one injection of BMSC every four days. Some cohorts were treated by I.P. injections with the drug ZM241385 (1.5mg/kg/day) every day for the duration of BMSC treatment. Post-treatment, mice were euthanized and their spleen was evaluated for human Th1 cell engraftment (A). Human Th1 cells from the spleen were stimulated ex-vivo for 4 hrs with PMA/ionomycin along with GolgiStop and GolgiPlug for the last 2 hrs. Cells were then stained for Intracellular cytokine expression. Representative flow cytometry plots for intracellular IFNγ and TNF-α staining (B). Cumulative absolute numbers of IFNγ-producing human Th1 cells (C) and TNF-α-producing human Th1 cells in the spleen (D). Cumulative histological findings in the lung and liver of treated animals (E). Data was pooled from two different experiments using two different BMSC donors. P values were obtained by performing a one way anova where *=P<0.05, **=P<0.01 and ***=P<0.001.